LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 5 von insgesamt 5

Suchoptionen

  1. Artikel: Antitumor Necrosis Factor-Alpha (TNF-

    Fonseca, Ashley / Sunny, Julee / Felipez, Lina M

    Case reports in pediatrics

    2021  Band 2021, Seite(n) 9989729

    Abstract: Crohn's disease (CD) is a chronic inflammatory disease that can be associated with intestinal and extraintestinal manifestations. Some patients are treated with infliximab, an antitumor necrosis factor-alpha (TNF- ...

    Abstract Crohn's disease (CD) is a chronic inflammatory disease that can be associated with intestinal and extraintestinal manifestations. Some patients are treated with infliximab, an antitumor necrosis factor-alpha (TNF-
    Sprache Englisch
    Erscheinungsdatum 2021-07-12
    Erscheinungsland United States
    Dokumenttyp Case Reports
    ZDB-ID 2659094-3
    ISSN 2090-6811 ; 2090-6803
    ISSN (online) 2090-6811
    ISSN 2090-6803
    DOI 10.1155/2021/9989729
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel: Very Early-Onset Inflammatory Bowel Disease (VEO-IBD) Presenting with Recurrent Leukocytoclastic Vasculitis Preceded by Streptococcal Pharyngitis.

    Fonseca, Ashley / Sunny, Julee / Felipez, Lina M

    Case reports in pediatrics

    2021  Band 2021, Seite(n) 1996430

    Abstract: Inflammatory bowel disease (IBD) that presents in children <6 years of age is known as very early-onset IBD (VEO-IBD). Extraintestinal manifestations in IBD, such as erythema nodosum (EN), pyoderma gangrenosum (PG), and, less likely, leukocytoclastic ... ...

    Abstract Inflammatory bowel disease (IBD) that presents in children <6 years of age is known as very early-onset IBD (VEO-IBD). Extraintestinal manifestations in IBD, such as erythema nodosum (EN), pyoderma gangrenosum (PG), and, less likely, leukocytoclastic vasculitis (LV), are more commonly present in Crohn's disease. Association between LV and ulcerative colitis (UC) is not commonly seen. We report a case of a 6-year-old female with a VEO-IBD UC phenotype presenting with multiple episodes of leukocytoclastic vasculitis, each preceded by streptococcal pharyngitis. Prior to the diagnosis of VEO-IBD, a skin biopsy was obtained and had shown leukocytoclastic vasculitis with a negative IgA stain. Initial laboratory results were remarkable for leukocytosis and increased anti-strep O and anti-DNase B titers. Gastrointestinal panel PCR demonstrated
    Sprache Englisch
    Erscheinungsdatum 2021-05-20
    Erscheinungsland United States
    Dokumenttyp Case Reports
    ZDB-ID 2659094-3
    ISSN 2090-6811 ; 2090-6803
    ISSN (online) 2090-6811
    ISSN 2090-6803
    DOI 10.1155/2021/1996430
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Can vulvar edema be the presenting sign of Crohn's disease? A case series.

    Rios Melendez, Sandra / Majluta, Aldo / Medina, Annette / Restrepo, Ricardo / Felipez, Lina M

    Journal of pediatric gastroenterology and nutrition

    2023  Band 78, Heft 2, Seite(n) 289–294

    Abstract: Vulvar involvement as an extraintestinal manifestation of Crohn's disease (CD) is a challenging diagnosis considering that vaginal findings may precede gastrointestinal symptoms. The aim of this study is to describe the clinical presentation, ... ...

    Abstract Vulvar involvement as an extraintestinal manifestation of Crohn's disease (CD) is a challenging diagnosis considering that vaginal findings may precede gastrointestinal symptoms. The aim of this study is to describe the clinical presentation, radiological findings, and treatment of vulvar Crohn's disease (VCD). We reviewed the time from initial presentation to diagnosis, presenting symptoms, radiological findings, gastrointestinal Crohn's disease Paris classification, and treatment response of five female pediatric patients. All the patients had radiological findings of vulvar inflammation on magnetic resonance imaging. Vaginal symptoms preceded gastrointestinal disease in two of the patients, which correlated with a delay in diagnosis. All patients had active disease on colonoscopy, with three of them having significant colorectal inflammation. Four of the patients were treated with infliximab, while one patient received ustekinumab with a resolution of their symptoms. In conclusion, VCD can precede gastrointestinal symptoms and is easily miss-diagnosed, leading to a delayed Crohn's disease diagnosis and treatment.
    Mesh-Begriff(e) Child ; Female ; Humans ; Crohn Disease/complications ; Crohn Disease/diagnosis ; Crohn Disease/drug therapy ; Edema/etiology ; Inflammation ; Infliximab/therapeutic use ; Vulvar Diseases/diagnosis ; Vulvar Diseases/etiology ; Vulvar Diseases/drug therapy
    Chemische Substanzen Infliximab (B72HH48FLU)
    Sprache Englisch
    Erscheinungsdatum 2023-12-10
    Erscheinungsland United States
    Dokumenttyp Case Reports ; Journal Article
    ZDB-ID 603201-1
    ISSN 1536-4801 ; 0277-2116
    ISSN (online) 1536-4801
    ISSN 0277-2116
    DOI 10.1002/jpn3.12059
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1728: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series.

    Sunny, Julee / Fonseca, Ashley G / Crim, Alisa Muñiz / Goyal, Alka / Felipez, Lina M

    JPGN reports

    2022  Band 3, Heft 2, Seite(n) e205

    Abstract: Ustekinumab (UST) is a human IgG1K monoclonal antibody that binds to the p40 receptor subunit bound by cytokines IL-12 and IL-23. It is indicated in both Crohn's disease and ulcerative colitis as a second-line agent. The safety and efficacy of UST in ... ...

    Abstract Ustekinumab (UST) is a human IgG1K monoclonal antibody that binds to the p40 receptor subunit bound by cytokines IL-12 and IL-23. It is indicated in both Crohn's disease and ulcerative colitis as a second-line agent. The safety and efficacy of UST in children and young adults has not been thoroughly studied. We report a case series of six pediatric patients and young adults who developed hypersensitivity reactions during intravenous infusion with UST. These reactions ranged from mild allergic reactions to anaphylaxis, with no detectable antibodies if tested. We hypothesize the reaction could be secondary to ethylenediaminetetraacetic acid, which is present solely in the intravenous preparation. Patients who experience hypersensitivity reactions during their UST infusion may safely receive subcutaneous preparations of UST, as demonstrated by some patients who received it based on physician discretion. Further investigation is required to establish the etiology of infusion reactions.
    Sprache Englisch
    Erscheinungsdatum 2022-04-27
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2691-171X
    ISSN (online) 2691-171X
    DOI 10.1097/PG9.0000000000000205
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  5. Artikel ; Online: Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab.

    Felipez, Lina M / Gokhale, Ranjana / Tierney, Matthew P / Kirschner, Barbara S

    Journal of pediatric gastroenterology and nutrition

    2012  Band 54, Heft 1, Seite(n) 28–33

    Abstract: Objective: The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents.: Patients and methods: A ... ...

    Abstract Objective: The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents.
    Patients and methods: A computerized database was used to identify children with CD who had failed conventional immunosuppression therapy and received thalidomide rescue therapy. Twelve patients, mean age at diagnosis 10 years, were identified. Eight children had disease localized to the ileum and colon and 4 to the gastroduodenal area and colon. Five cases were complicated by strictures and 7 by fistulae. Previous drug therapy included azathioprine/6-mercaptopurine (11/12), methotrexate (7/12), and anti-TNF biologics (12/12). Outcome measures were Harvey-Bradshaw Index, change in prednisone dose, hospitalizations, bowel resections, and incision and drainage procedures. Laboratory evaluations were calculated before and after 1 to 6 months of thalidomide.
    Results: Mean Harvey-Bradshaw Index score improved from 11.8 to 3.9 (P = 0.0004), mean prednisone dose decreased from 13.9 to 2.3  mg/day (P = 0.001), mean number of hospitalizations decreased from 6.3 to 1.3 (P = 0.002), and erythrocyte sedimentation rate decreased from 35 to 14  mm/h (P = 0.02). The surgery rate pre-thalidomide was 0.031 and on thalidomide was 0.004. Of the 7 patients with fistulae, 5 had complete fistula closure, 1 had partial closure, and 1 showed no improvement. Adverse reactions that resulted in discontinuation of thalidomide are as follows: 42% peripheral neuropathy, 17% worsening of the CD, 8% dizziness, and 8% allergic reaction. All 5 patients who developed peripheral neuropathy had clinical resolution of the neurologic symptoms within 2 to 3 months after stopping thalidomide.
    Conclusions: Thalidomide is a potentially effective rescue therapy for severe refractory CD in children who fail to respond to anti-TNF medications.
    Mesh-Begriff(e) Adalimumab ; Adolescent ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Blood Sedimentation/drug effects ; Child ; Child, Preschool ; Constriction, Pathologic ; Crohn Disease/drug therapy ; Crohn Disease/pathology ; Crohn Disease/surgery ; Disease Progression ; Female ; Fistula/drug therapy ; Fistula/surgery ; Hospitalization/statistics & numerical data ; Humans ; Hypersensitivity, Immediate/etiology ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/pharmacology ; Immunosuppressive Agents/therapeutic use ; Infliximab ; Intestines/drug effects ; Intestines/pathology ; Male ; Outcome Assessment (Health Care) ; Peripheral Nervous System Diseases/etiology ; Prednisone/administration & dosage ; Prednisone/therapeutic use ; Retrospective Studies ; Severity of Illness Index ; Thalidomide/adverse effects ; Thalidomide/pharmacology ; Thalidomide/therapeutic use ; Treatment Outcome
    Chemische Substanzen Anti-Inflammatory Agents ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Immunosuppressive Agents ; Thalidomide (4Z8R6ORS6L) ; Infliximab (B72HH48FLU) ; Adalimumab (FYS6T7F842) ; Prednisone (VB0R961HZT)
    Sprache Englisch
    Erscheinungsdatum 2012-01
    Erscheinungsland United States
    Dokumenttyp Evaluation Studies ; Journal Article
    ZDB-ID 603201-1
    ISSN 1536-4801 ; 0277-2116
    ISSN (online) 1536-4801
    ISSN 0277-2116
    DOI 10.1097/MPG.0b013e318228349e
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1728: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang